Chemotherapy followed by letrozole sets standard for advanced, low-grade serous gynecologic carcinoma
Late-breaking results from the Phase III NRG GY019 trial indicate that letrozole monotherapy (L) did not demonstrate noninferiority to paclitaxel/carboplatin followed by letrozole (PC/L) for progression-free survival (PFS) ...
Apr 13, 2026
0
2









